Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 7/2018

Open Access 01-07-2018 | Original Research Article

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist

Authors: Przemysław Holko, Paweł Kawalec, Andrzej Pilc

Published in: PharmacoEconomics | Issue 7/2018

Login to get access

Abstract

Objective

The aim was to evaluate the cost-effectiveness of Crohn’s disease (CD) treatment with vedolizumab and ustekinumab after failure of therapy with tumor necrosis factor-α antagonists (anti-TNFs).

Methods

The Markov model incorporated the lifetime horizon, synthesis-based estimates of biologics’ efficacy in relation to anti-TNF exposure, and administration of biologics reflecting clinical practice (e.g., sequence of biologics, retreatment, 12-month treatment). The utilities, non-medical costs and indirect costs were derived from a study of 200 adult patients with CD, while the healthcare costs were from a study of 1393 adults with CD who used biologics in Poland. The quality-adjusted life years (QALYs) and costs (the societal perspective) were discounted with the annual rates of 3.5 and 5%, respectively.

Results

The addition of vedolizumab (ustekinumab) to the sequence of available anti-TNFs (after first-line infliximab or after second-line adalimumab) led to a gain of 0.364 (0.349) QALYs at an additional cost of €5600.24 (€6593.82). The incremental cost-effectiveness ratios (ICERs) were €15,369 [95% confidence interval (CI) 7496–61,354] and €18,878 (95% CI 9213–85,045) per QALY gained with vedolizumab and ustekinumab, respectively. Sensitivity analyses revealed a high impact on the ICERs of the relapse rate after discontinuation of biologic treatment. The highest value of vedolizumab/ustekinumab was estimated after the failure of therapies with both anti-TNFs.

Conclusions

CD treatment with ustekinumab or vedolizumab after failure of anti-TNF therapy appears to be cost-effective at a threshold of €31,500. The replacement of the second-line anti-TNF with ustekinumab/vedolizumab and the course of the disease after discontinuation of biologics are influential drivers of the cost-effectiveness.
Appendix
Available only for authorised users
Literature
1.
de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27.CrossRefPubMed
2.
Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52(2):141–50.CrossRefPubMed
3.
Erim DO, Mahendraratnam N, Okafor PN, Wheeler SB. The value of vedolizumab as rescue therapy in moderate-severe Crohn’s disease patients with adalimumab non-response in the USA. J Crohns Colitis. 2015;9(8):669–75.CrossRefPubMed
4.
Rencz F, Gulácsi L, Péntek M, et al. Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe. Expert Rev Pharmacoecon Outcomes Res. 2017;17(6):597–606.CrossRefPubMed
5.
Baji P, Gulácsi L, Péntek M, et al. Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe. United Eur Gastroenterol J. 2018;6(2):310–21.CrossRef
6.
Hodgson R, Walton M, Biswas M, et al. Ustekinumab for treating moderately to severely active Crohn’s disease after prior therapy: an evidence review group perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2018;36(4):387–98.CrossRefPubMed
7.
Rafia R, Scope A, Harnan S, et al. Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy: an evidence review group perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2016;34(12):1241–53.CrossRefPubMed
8.
Moćko P, Kawalec P, Smela-Lipińska B, Pilc A. Effectiveness and safety of vedolizumab for treatment of Crohn’s disease: a systematic review and meta-analysis. Arch Med Sci. 2016;12(5):1088–96.CrossRefPubMedPubMedCentral
9.
Péntek M, Lakatos PL, Oorsprong T, et al. Access to biologicals in Crohn’s disease in ten European countries. World J Gastroenterol. 2017;23(34):6294–305.CrossRefPubMedPubMedCentral
10.
Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30(3):265–74.CrossRefPubMed
11.
Gisbert JP, Marín AC, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther. 2015;42(4):391–405.CrossRefPubMed
12.
Casanova MJ, Chaparro M, García-Sánchez V, et al. Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-term follow-up study. Am J Gastroenterol. 2017;112(1):120–31.CrossRefPubMed
13.
Holko P, Kawalec P, Mossakowska M, Pilc A. Health-related quality of life impairment and indirect cost of Crohn’s disease: a self-report study in Poland. PLoS One. 2016;11(12):e0168586.CrossRefPubMedPubMedCentral
14.
Jonsson B Ten. Arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10:357–9.CrossRefPubMed
15.
Marchetti M, Liberato NL. Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of model-based analyses. Expert Rev Pharmacoecon Outcomes Res. 2014;14:815–24.CrossRefPubMed
16.
European Medicines Agency. Summary of Product Characteristics: Entyvio, Stelara, Remicade, Remsima, Inflectra, Humira. www.​ema.​europa.​eu. Accessed 19 Dec 2017.
17.
Holko P, Kawalec P, Stawowczyk E. Prevalence and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012–2014: an analysis of nationwide databases. Eur J Gastroenterol Hepatol. 2018;30(4):456–64.CrossRefPubMed
18.
The Agency for Health Technology Assessment and Tariff System. Health technology assessment guidelines. Version 3.0. www.​aotm.​gov.​pl. Accessed 19 Dec 2017.
19.
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.CrossRefPubMed
20.
Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–35.CrossRefPubMed
21.
Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. Gastroenterology. 2015;148(2):344–54.CrossRefPubMed
22.
Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–27.CrossRefPubMed
23.
Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–60.CrossRefPubMed
24.
Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367(16):1519–28.CrossRefPubMed
25.
Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. Vedolizumab as induction and maintenance therapy for Crohn’s disease in patients naïve to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis. 2017;23(1):97–106.CrossRefPubMed
26.
Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–85.CrossRefPubMed
27.
Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117(4):761–9.CrossRefPubMed
28.
Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398–405.CrossRefPubMed
29.
Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–33.CrossRefPubMed
30.
Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–38.CrossRefPubMed
31.
Golicki D, Niewada M. General population reference values for 3-level EQ-5D (EQ-5D-3L) questionnaire in Poland. Pol Arch Med Wewn. 2015;125(1–2):18–26.PubMed
32.
33.
Narodowy Fundusz Zdrowia. Announcement from the Department of Medicinal Products, 27 September 2017. www.​nfz.​gov.​pl. Accessed 19 Dec 2017.
34.
Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, Harmsen WS, Zinsmeister AR. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117(1):49–57.CrossRefPubMed
35.
Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technol Assess. 2011;15(6).
36.
Central Statistical Office of Poland. Life table, 2016. stat.gov.pl. Accessed 19 Dec 2017.
37.
Odes S, Vardi H, Friger M, et al. Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn’s disease patients by Markov analysis. Aliment Pharmacol Ther. 2010;31(7):735–44.CrossRefPubMed
38.
Kawalec P, Moćko P, Malinowska-Lipien I, Brzostek T. Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn’s disease patients: a systematic review and meta-analysis. J Comp Eff Res. 2017;6(7):601–12.CrossRefPubMed
39.
Holko P, Kawalec P, Mossakowska M. Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study. Eur J Gastroenterol Hepatol. 2018;30(2):174–80.CrossRefPubMed
40.
Central Statistical Office of Poland. Statistical Bulletins. www.stat.gov.pl. Accessed 19 Dec 2017.
41.
Narodowy Bank Polski (Central Bank of Poland). Weighted average rates of foreign currencies in PLN. nbp.pl. Accessed Dec 19, 2017.
42.
Holko P. Comment on: “Forecasting pharmaceutical prices for economic evaluations when there is no market: a review”. PharmacoEconomics Open. 2017;1(1):69–70.CrossRefPubMedPubMedCentral
43.
Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231–50.CrossRefPubMed
Metadata
Title
Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
Authors
Przemysław Holko
Paweł Kawalec
Andrzej Pilc
Publication date
01-07-2018
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 7/2018
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-018-0653-2

Other articles of this Issue 7/2018

PharmacoEconomics 7/2018 Go to the issue

Letter to the Editor

Comment on: “A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis”

Original Research Article

Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England

Review Article

Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Systematic Review

The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review

Review Article

Discounting in Economic Evaluations

Editorial

Should Low- and Middle-Income Countries Adopt Clinical Guidelines Developed in ‘Rich’ Countries?